F. Raal

Publications340
h-index59
Citations20,326
Highly Influential Citations735
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Watts
  • 1,094 Publications • 41,264 Citations
  • J. Kastelein
  • 949 Publications • 83,510 Citations
  • R. Hegele
  • 1,100 Publications • 53,025 Citations
  • G. Hovingh
  • 321 Publications • 18,522 Citations
  • Publications
  • Influence
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
TLDR
There is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition, familial hypercholesterolaemia.
View PDF
Low-density lipoproteins cause atherosclerotic cardiovascular disease
Ference, Brian A.; Ginsberg, Henry N.; Graham, Ian; Ray, Kausik K.; Packard, Chris J.; Bruckert, Eric; Hegele, Robert A.; Krauss, Ronald M.; Raal, Frederick J.; Schunkert, Heribert; Watt, Gerald F.;…
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
TLDR
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels and there was evidence of a reduction in the rate of cardiovascular events.
View on PubMed
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
TLDR
During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis.
View on PubMed
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
TLDR
The Panel proposes to identify SAMS by symptoms typical of statin myalgia and their temporal association with discontinuation and response to repetitive statin re-challenge, and recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets.
View PDF
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
View on Elsevier
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
View on Elsevier
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind,…
View on Elsevier
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
View on PubMed
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial…
TLDR
The need for early identification of HoFH patients, prompt referral to specialized centres, and early initiation of appropriate treatment is highlighted, and recommendations offer guidance for a wide spectrum of clinicians who are often the first to identify patients with suspected HoFH.
View PDF
...
...